Amalgamated Bank Sells 1,130 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Amalgamated Bank lessened its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 3.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,290 shares of the medical research company’s stock after selling 1,130 shares during the period. Amalgamated Bank’s holdings in Quest Diagnostics were worth $3,901,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. NBC Securities Inc. bought a new stake in Quest Diagnostics during the third quarter worth $25,000. VisionPoint Advisory Group LLC boosted its stake in Quest Diagnostics by 100.0% in the third quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares in the last quarter. BKM Wealth Management LLC bought a new position in Quest Diagnostics in the fourth quarter valued at about $29,000. Alaska Permanent Fund Corp raised its stake in Quest Diagnostics by 79.3% during the fourth quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock worth $33,000 after acquiring an additional 107 shares in the last quarter. Finally, Headinvest LLC acquired a new stake in shares of Quest Diagnostics in the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Down 0.6 %

DGX opened at $136.15 on Thursday. Quest Diagnostics Incorporated has a twelve month low of $119.59 and a twelve month high of $145.58. The company has a fifty day moving average of $130.94 and a 200-day moving average of $132.04. The stock has a market cap of $15.12 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.18. The firm had revenue of $2.37 billion during the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The business’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period last year, the company posted $2.04 EPS. On average, sell-side analysts predict that Quest Diagnostics Incorporated will post 8.78 EPS for the current year.

Insider Activity

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares in the company, valued at $4,843,610.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, SVP Michael E. Prevoznik sold 661 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $83,378.54. Following the completion of the sale, the senior vice president now owns 40,206 shares in the company, valued at $5,071,584.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael E. Prevoznik sold 5,611 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares in the company, valued at $4,843,610.64. The disclosure for this sale can be found here. Insiders sold a total of 16,910 shares of company stock worth $2,159,602 over the last quarter. 0.79% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Mizuho increased their price objective on shares of Quest Diagnostics from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Leerink Partnrs reiterated a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. TheStreet lowered Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th. Truist Financial increased their target price on Quest Diagnostics from $145.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, April 24th. Finally, UBS Group raised their price objective on shares of Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Ten research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $146.17.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.